RPID earnings

Reports first quarter 2026 total revenue of $8.0 million, representing 11% growth compared to the first quarter of 2025 Placed 6 Growth Direct systems in the first quarter 2026 compared to 3 systems in the first quarter of 2025 First quarter 2026 product revenue increased 36% year-over-year; consumable revenue increased over 30% First quarter 2026 recurring revenue increased 28% year-over-year; comprised 63% of total revenueFirst quarter 2026 product gross margin percentage increased 15-percentage points; consumable gross margin increased 33-percentage pointsAdvanced strategic collaboration with MilliporeSigma with execution of Services AgreementReaffirms full year 2026 total revenue guidanc

LEXINGTON, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2026 financial results after the market close on Wednesday, May 13, 2026. In conjunction with the release, the Company's management team will host a webcast conference call at 4:30 p.m. ET on Wednesday, May 13, 2026. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for replay a

Reports record fourth quarter 2025 total revenue of $11.3 million, representing 37% growth compared to fourth quarter 2024Reports full year 2025 total revenue of $33.6 million, representing 20% growth compared to 2024Amgen expands global Growth Direct system rollout with significant multi-system order in the fourth quarter 2025; will sponsor North American Growth Direct Day in the second quarter 2026Samsung Biologics continues to expand Growth Direct deployment across its manufacturing network with a meaningful multi-system order in the first quarter 2026For the full year 2026, the Company expects total revenue in the range of $37.0 million to $41.0 million including a range of 30 to 38 Grow

LEXINGTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2025 financial results prior to the market open on Thursday, March 12, 2026. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Thursday, March 12, 2026. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and av

Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, increased 32% compared to the third quarter of 2024 driven by record consumable revenue. Reports third quarter gross margin of 9%, representing a 70-basis point improvement compared to the third quarter of 2024.Announces record multi-system order from an existing Top 20 global biopharma customer to automate global manufacturing network. Raises full year 2025 total revenue guidance to at least $33.0 million, which assumes at least 27 Growth Direct system placements. LEXINGTON, Mas

LEXINGTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2025 financial results prior to the market open on Friday, November 7, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, November 7, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for rep

Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024. Reports second quarter gross margin of 4%, representing a seven-percentage point improvement compared to the second quarter of 2024. Enters into five-year, $45 million term loan facility with $20 million funded at close. Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology c

LEXINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2025 financial results prior to the market open on Tuesday, August 12, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Tuesday, August 12, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for re

Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma"). Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Compa

LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 9, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for replay after

Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue increased by 27% compared to the fourth quarter of 2023.Announces full year 2024 total revenue of $28.1 million, representing 25% growth compared to 2023; recurring revenue increase by 14% compared to 2023.Reports record fourth quarter gross margin of 12%, representing a 15-percentage point improvement over the fourth quarter of 2023; full year 2024 gross margin increased 24 percentage points compared to 2023.Announces global Distribution and Collaboration Agreement with MilliporeSigma LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro

LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2024 financial results prior to the market open on Friday, February 28, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:00 a.m. ET on Friday, February 28, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and

Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24% compared to the third quarter of 2023Placed seven Growth Direct® systems in the third quarter of 2024, marking the highest number of system placements since the third quarter of 2021 Included a multi-system order at an additional site of an existing top 20 global pharma customer as part of their global Growth Direct system rollout Achieved inflection in gross margins to positive 8%, representing a significant company milestone and a 35 percentage point improvement compared to the third quarter of 2023Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 2

LEXINGTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2024 financial results prior to the market open on Friday, November 1, 2024. In conjunction with the release, the Company's management team will host a webcast conference call beginning at 9:00 a.m. ET on Friday, November 1, 2024. The live audio webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. A

Record second quarter 2024 revenue of $6.6 million, representing growth of 32% compared to the second quarter of 2023150th Growth Direct® system placed with an existing top 15 global pharma customer First Growth Direct Rapid Sterility system placed with an existing top 10 global pharma customerGross margin improved by 35 percentage points compared to the second quarter of 2023, and by 24 percentage points compared to the first quarter of 2024Announces operational efficiency program that is expected to enable the Company to achieve positive cash flow without additional financingReaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compa

LOWELL, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2024 financial results prior to the market open on Friday, August 2, 2024. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, August 2, 2024. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. About Rapid Micro Biosy

Reports first quarter 2024 total revenue of $5.6 million, representing growth of 11% compared to first quarter 2023 Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023 LOWELL, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the first quarter ended March 31, 2024. Recent Highlights First quarter total revenue (combined product a

LOWELL, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2024 financial results prior to the market open on Friday, May 3, 2024. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 3, 2024. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. About Rapid Micro Biosyst

Reports fourth quarter 2023 total revenue of $6.3 million, representing 45% growth compared to fourth quarter 2022 Reports 2023 revenue of $22.5 million, representing 31% growth compared to 2022 Delivered 2023 recurring revenue of $13.5 million, representing 23% growth compared to 2022 Provides 2024 revenue guidance of at least $27.0 million, representing at least 20% growth compared to 2023 LOWELL, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, toda

LOWELL, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2023 financial results prior to the market open on Friday, March 1, 2024. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, March 1, 2024. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. About Rapid

Reports third quarter 2023 total revenue of $6.1 million, representing growth of 30% compared to third quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30% compared to full year 2022 LOWELL, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the third quarter ended September 30, 2023. Recent Highlights Third quarter total revenue (combined

LOWELL, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2023 financial results prior to the market open on Friday, November 3, 2023. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, November 3, 2023. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. About Rapid Micr

Reports second quarter 2023 total revenue of $5.0 million, representing growth of 30% compared to second quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30% compared to full year 2022 LOWELL, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2023. Recent Highlights Second quarter total revenue (combined p

LOWELL, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second-quarter 2023 financial results prior to the market open on Friday, August 4, 2023. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. EST on Friday, August 4, 2023. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. About Rapid Micro Bios

Reports first quarter 2023 total revenue of $5.0 million, representing growth of 21%, compared to first quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30%, compared to full year 2022 LOWELL, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the first quarter ended March 31, 2023. Recent Highlights First quarter total revenue (combined pro

LOWELL, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2023 financial results prior to the market open on Friday, May 5, 2023. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. EST on Friday, May 5, 2023. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. About Rapid Micro Biosys

Reports fourth quarter 2022 commercial revenue of $4.4 million Reports full year 2022 commercial revenue of $17.1 million Delivered full year 2022 recurring commercial revenue of $11.0 million, representing 40% growth Provides full year 2023 commercial revenue guidance of at least $22.0 million, representing growth of approximately 30% LOWELL, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the fourth quarter

LOWELL, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2022 financial results prior to the market open on Friday, March 3, 2023. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. EST on Friday, March 3, 2023.   The live and archived webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast da

LOWELL, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2022 financial results on Thursday, November 10th, prior to the market open. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. EST on Thursday, November 10, 2022.   The live and archived webcast is accessible on the Company's website here and will be available for replay for one year. About Rapid Micro Biosystems

Rejects Unsolicited, Non-Binding Proposal from Kennedy Lewis Investment Management Adopts Limited Duration Stockholder Rights Plan LOWELL, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that its Board of Directors has initiated a review of strategic alternatives to maximize shareholder value. The Board has retained Morgan Stanley & Co. LLC as its financial advisor and Goodwin Procter LLP as its legal advisor to assist in its review of a w

LOWELL, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2022 financial results on Friday, August 12, prior to the market open. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. EST on Friday, August 12, 2022.   The live and archived webcast is accessible on the Company's website here and will be available for replay for one year. About Rapid Micro Biosystems Rapid M

LOWELL, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2022 financial results on Tuesday, May 10, 2022, prior to the market open. In conjunction with the release, Rapid's management team will host a webcast conference call at 8:30 a.m. EDT on Tuesday, May 10, 2022. The live call is accessible on the Company's website at investors.rapidmicrobio.com/ and will be archived and available for replay for one year. About R

LOWELL, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) ("Rapid Micro" or the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2021 financial results on Friday, March 4, 2022, prior to the market open. In conjunction with the release, Rapid Micro's management team will host a webcast conference call at 8:30 a.m. EST on Friday, March 4, 2022.   The live call will be accessible on the Company's website at investors.rapidmicrobio.com and will be archived and available fo

LOWELL, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) ("Rapid Micro" or the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it will release financial results for the third quarter of 2021 after market close on Thursday, November 11, 2021. Conference Call Details Company management will host a webcast conference call to discuss third quarter 2021 financial results beginning at 5:00am Pacific Time/8:00am Eastern Time on Friday, November 12, 2021. The conference call will be available to

LOWELL, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it will release financial results for the second quarter of 2021 after market close on Thursday, August 26, 2021. Conference Call Details Company management will host a webcast conference call to discuss second quarter 2021 financial results beginning at 1:30pm Pacific Time/4:30 p.m. Eastern Time on August 26, 2021. The conference call will be available to investors via live webc